Ultrasound study aims to see if new Crohn's drug heals from the inside out
NCT ID NCT07308067
Summary
This study is observing how well the medication risankizumab (SKYRIZI) heals the full thickness of the bowel wall in adults with Crohn's disease. Researchers will use intestinal ultrasound scans, which are easier for patients than repeated colonoscopies, to measure healing at 4 and 12 weeks after starting treatment. The goal is to see if achieving this deeper 'transmural healing' leads to better long-term outcomes like fewer hospitalizations and surgeries.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amiens university hospital
RECRUITINGAmiens, France
Contact
-
Clermont-Ferrand University hospital
RECRUITINGClermont-Ferrand, France
Contact
-
Grenoble university hospital
RECRUITINGGrenoble, France
Contact
-
Marseille University Hospital
RECRUITINGMarseille, France
Contact
Conditions
Explore the condition pages connected to this study.